Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 4/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL790190 | 0.81 | CASP3 (0.49) | CASP1ALDH1A1GAACTSLCTSB | |
| SCHEMBL19207724 | 0.78 | PLA2G7 (0.33) | — | |
| SCHEMBL12873896 | 0.77 | CASP1 (0.44) | CASP1CTSKCASP3EPHX1 | |
| SCHEMBL14320141 | 0.77 | ALDH1A1 (0.51) | CASP1ALDH1A1GAACTSLCTSB | |
| SCHEMBL10265005 | 0.77 | CTSK (0.49) | ALDH1A1GAACTSLCTSBCTSK | |
| SCHEMBL31039728 | 0.77 | CTSL (0.57) | ALDH1A1GAACTSLCTSBCTSK | |
| SCHEMBL31039731 | 0.77 | CTSL (0.57) | ALDH1A1GAACTSLCTSBCTSK | |
| SCHEMBL795453 | 0.75 | FPR2 (0.52) | CASP1CTSLCTSKCASP3 | |
| SCHEMBL795454 | 0.75 | FPR2 (0.52) | CASP1CTSLCTSKCASP3 | |
| SCHEMBL19207654 | 0.75 | RIPK1 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388601-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12358928-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20240150376-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-20230043400-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20200317691-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-10604535-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190112318-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2019-04-18 | — | — | US | disclosed |
| US-10131676-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180099981-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2018-04-12 | — | — | US | disclosed |
| US-9896458-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20180022759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2018-01-25 | — | — | US | disclosed |
| US-9815850-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2017-11-14 | — | — | US | disclosed |
| WO-2017136727-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| US-20170226127-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099981-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | CASP1 2041/4885ALDH1A1 4405/4885GAA 2016/4885 |
| US-20250388601-A1 | Compounds, Compositions and Methods | AURKC, WEE2, ERBB2 | CASP1 2775/4885ALDH1A1 3854/4885GAA 2997/4885 |
| US-20200317691-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | CASP1 2041/4885ALDH1A1 4405/4885GAA 2016/4885 |
| US-20240150376-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | CASP1 2041/4885ALDH1A1 4405/4885GAA 2016/4885 |
| US-12358928-B2 | Compounds, compositions and methods | PIK3CA, PLK1, PIK3CB | CASP1 2041/4885ALDH1A1 4405/4885GAA 2016/4885 |
| US-10131676-B2 | Compounds, compositions and methods | PIK3CA, PLK1, PIK3CB | CASP1 2041/4885ALDH1A1 4405/4885GAA 2016/4885 |
| US-20230043400-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | CASP1 2041/4885ALDH1A1 4405/4885GAA 2016/4885 |
| US-20180022759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | CASP1 2041/4885ALDH1A1 4405/4885GAA 2016/4885 |
| US-20170226127-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | CASP1 2041/4885ALDH1A1 4405/4885GAA 2016/4885 |
| US-10604535-B2 | Compounds, compositions and methods | PIK3CA, PLK1, PIK3CB | CASP1 2041/4885ALDH1A1 4405/4885GAA 2016/4885 |
| US-20190112318-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | CASP1 2041/4885ALDH1A1 4405/4885GAA 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.